Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Safety Profile of Two Commercially Available Red Laser Light Devices for Myopia
Author Affiliations & Notes
  • Lisa A Ostrin
    University of Houston College of Optometry, Houston, Texas, United States
  • Alexander W Schill
    University of Houston College of Optometry, Houston, Texas, United States
  • Lucy Zhuo Chen
    Private practice, Houston, Texas, United States
  • Footnotes
    Commercial Relationships   Lisa Ostrin Vyluma, Code C (Consultant/Contractor), Zeiss, Code C (Consultant/Contractor), Meta, Code F (Financial Support), Topcon, Code F (Financial Support), US 11375890 B2, Code P (Patent); Alexander Schill None; Lucy Chen None
  • Footnotes
    Support  NEI R01EY030193 and NEI P30EY007551
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6620. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lisa A Ostrin, Alexander W Schill, Lucy Zhuo Chen; Safety Profile of Two Commercially Available Red Laser Light Devices for Myopia. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6620.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Low level red light laser (LLRL) therapy is an emerging treatment for myopia that shows promising results in published studies. In LLRL, children are instructed to look into an instrument emitting a red laser for 3 minutes twice a day, 5 days a week, for the duration of the treatment period, which could be on the order of years. Numerous devices are currently available and actively used in China. However, the safety profile of these devices has not been fully investigated. The goal of this study was to characterize the output and determine thermal and photochemical maximum permissible exposure time for two different red light devices being used for myopia control.

Methods : LLRL devices from two different manufacturers were obtained. For each device, power was determined through a 7 mm aperture by placing the sensor of a radiometer 10 cm from the output of the source. Corneal and retinal irradiance were calculated. ANSI Z136.1-2014 standards were used to determine laser class, and luminance dose restrictions (Morgan, 2008; ANSI Z136.1-2014, 8.3.3.) were applied to calculate maximum permissible exposure time (DeLori, 2007).

Results : Both devices were determined to be Class 1 and within the safety limits for thermal damage. Figure 1 shows the maximum permissible exposure time using the luminance dose restrictions outlined in section 8.3.3. ANSI 2014, which states that any exposure over 100 seconds must be less than 5 J/cm2/V(λ) to avoid photochemical damage to the retina. Device 1 was measured to have a wavelength of 654 nm, power of 0.2 mW (Ø7 mm, 10 cm away), corneal irradiance of 0.52 mW/cm2, and retinal irradiance of 3.2 W/cm2. The maximum permissible exposure time for a 2 mm pupil was 31.3 s and for a 7 mm pupil was 2.3 s. Device 2 had a wavelength of 652 nm, power of 0.06 mW, corneal irradiance of 0.156 mW/cm2, and retinal irradiance of 0.96 W/cm2. The maximum permissible exposure time for a 2 mm pupil was 104.2 s and for a 7 mm pupil was 8.51 s.

Conclusions : The two different LLRL devices examined were found to be Class 1 and within the safety limits for thermal damage. However, luminance dose restrictions suggest that maximal permissible exposure time for direct viewing is 2-104 seconds, depending on device and pupil size. Therefore, 3 minutes of continuous viewing surpasses maximal permissible exposure time, putting the retina at risk for photochemical damage.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×